Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523585 · ClinicalTrials.gov registry record · Phase 3
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 608
- Enrollment target
NCT03523585 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 608 participants.
The verdict
NCT03523585, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 608 participants
- Enrollment target
Study Summary
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: * cannot be removed by an operation * has spread to other parts of the body
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Trastuzumab deruxtecan
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03523585
The ClinicalTrials.gov registry entry for NCT03523585 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT03523585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03523585 about?
NCT03523585 is a clinical study titled "DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]". This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: * cannot be removed by an operation * has spread to other parts of the body
What is the current status of trial NCT03523585?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 608 participants. The study started on 2018-08-01. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT03523585?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Trastuzumab deruxtecan (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT03523585?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.